Cardiovascular Manifestation of Paediatric HIV Infection
- 22 Downloads
Prior to effective antiretroviral therapy (ART), HIV infected children demonstrated poorer ventricular function and higher ventricular masses than uninfected children. Those with the poorest myocardial function had the poorest outcomes. Effective ART improved survival as well as myocardial function. However, over time, myocardial function appears to decline. In addition, accelerated coronary artery disease, related to the effects of HIV, as well as its treatment, pose a new set of challenges as these patients approach adulthood. In untreated or inadequately treated patients, the prevalence of overt myocardial dysfunction, pericardial disease and primary as well as secondary pulmonary hypertension are significantly higher and need to be recognised and managed appropriately.
KeywordsHuman immunodeficiency virus Paediatric Cardiovascular Cardiomyopathy Pericarditis Pulmonary hypertension
- 2.Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection (P2C2 HIV) STUDY GROUP. Circulation. 2000;102(13):1542–8.CrossRefGoogle Scholar
- 3.Langston C, Cooper ER, Goldfarb J, Easley KA, Husak S, Sunkle S, et al. Human immunodeficiency virus-related mortality in infants and children: data from the pediatric pulmonary and cardiovascular complications of vertically transmitted HIV (P(2)C(2)) study. Pediatrics. 2001;107(2):328–38.CrossRefGoogle Scholar
- 5.Lipshultz SE, Williams PL, Wilkinson JD, Leister EC, Van Dyke RB, Shearer WT, et al. Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the adolescent master protocol of the multicenter pediatric HIV/AIDS cohort study. JAMA Pediatr. 2013;167(6):520–7.CrossRefGoogle Scholar
- 7.Barbaro G. HIV-associated cardiomyopathy. Herz Kardiovaskuläre Erkrankungen. 2005;30:486–92.Google Scholar
- 14.Alabed S, Sabouni A, Al Dakhoul S, Bdaiwi Y, Frobel-Mercier AK. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev. 2016;1:CD007037.Google Scholar
- 15.Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;37(1):67–119.CrossRefGoogle Scholar
- 16.Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, Voelkel NF, Flores SC. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med. 2006;174:437–45. https://doi.org/10.1164/rccm.200601-005OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. https://aidsinfo.nih.gov/guidelines/htmltables/2/6152. Accessed 14 Mar 2019.